IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

医学 安慰剂 内科学 人口 肾脏疾病 生物标志物 随机对照试验 临床试验 病理 替代医学 化学 生物化学 环境卫生
作者
Paul M. Ridker,Matt Devalaraja,Florian M.M. Baeres,Mads D.M. Engelmann,G. Kees Hovingh,Milana Ivkovic,Larry Lo,Douglas F. Kling,Pablo E. Pérgola,Dominic S. Raj,Peter Libby,Michael Davidson
出处
期刊:The Lancet [Elsevier BV]
卷期号:397 (10289): 2060-2069 被引量:737
标识
DOI:10.1016/s0140-6736(21)00520-1
摘要

Background IL-6 has emerged as a pivotal factor in atherothrombosis. Yet, the safety and efficacy of IL-6 inhibition among individuals at high atherosclerotic risk but without a systemic inflammatory disorder is unknown. We therefore addressed whether ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand, safely and effectively reduces biomarkers of inflammation and thrombosis among patients with high cardiovascular risk. We focused on individuals with elevated high-sensitivity CRP and chronic kidney disease, a group with substantial unmet clinical need in whom previous studies in inflammation inhibition have shown efficacy for cardiovascular event reduction. Methods RESCUE is a randomised, double-blind, phase 2 trial done at 40 clinical sites in the USA. Inclusion criteria were age 18 years or older, moderate to severe chronic kidney disease, and high-sensitivity CRP of at least 2 mg/L. Participants were randomly allocated (1:1:1:1) to subcutaneous administration of placebo or ziltivekimab 7·5 mg, 15 mg, or 30 mg every 4 weeks up to 24 weeks. The primary outcome was percentage change from baseline in high-sensitivity CRP after 12 weeks of treatment with ziltivekimab compared with placebo, with additional biomarker and safety data collected over 24 weeks of treatment. Primary analyses were done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. The trial is registered with ClinicalTrials.gov, NCT03926117. Findings Between June 17, 2019, and Jan 14, 2020, 264 participants were enrolled into the trial, of whom 66 were randomly assigned to each of the four treatment groups. At 12 weeks after randomisation, median high-sensitivity CRP levels were reduced by 77% for the 7·5 mg group, 88% for the 15 mg group, and 92% for the 30 mg group compared with 4% for the placebo group. As such, the median pairwise differences in percentage change in high-sensitivity CRP between the ziltivekimab and placebo groups, after aligning for strata, were –66·2% for the 7·5 mg group, –77·7% for the 15 mg group, and –87·8% for the 30 mg group (all p<0·0001). Effects were stable over the 24-week treatment period. Dose-dependent reductions were also observed for fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein(a). Ziltivekimab was well tolerated, did not affect the total cholesterol to HDL cholesterol ratio, and there were no serious injection-site reactions, sustained grade 3 or 4 neutropenia or thrombocytopenia. Interpretation Ziltivekimab markedly reduced biomarkers of inflammation and thrombosis relevant to atherosclerosis. On the basis of these data, a large-scale cardiovascular outcomes trial will investigate the effect of ziltivekimab in patients with chronic kidney disease, increased high-sensitivity CRP, and established cardiovascular disease. Funding Novo Nordisk.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
業業发布了新的文献求助10
1秒前
1秒前
RRR关注了科研通微信公众号
1秒前
Aurora发布了新的文献求助10
1秒前
情怀的应助被daylight采纳,获得10
2秒前
DW发布了新的文献求助10
2秒前
DW发布了新的文献求助10
2秒前
DW发布了新的文献求助10
3秒前
XIAOLI发布了新的文献求助20
3秒前
DW发布了新的文献求助10
3秒前
3秒前
cookie0312完成签到,获得积分10
3秒前
zz发布了新的文献求助10
4秒前
铁子发布了新的文献求助10
5秒前
5秒前
5秒前
香蕉觅云的应助被单薄冰安采纳,获得10
5秒前
DW发布了新的文献求助10
6秒前
DW发布了新的文献求助10
6秒前
6秒前
DW发布了新的文献求助10
6秒前
6秒前
DW发布了新的文献求助10
6秒前
科研通AI6.4的应助被默z采纳,获得10
6秒前
DW发布了新的文献求助10
6秒前
7秒前
科研通AI65的应助被111采纳,获得10
7秒前
8秒前
小C完成签到 ,获得积分10
8秒前
打打的应助被白椽采纳,获得10
8秒前
DW发布了新的文献求助10
9秒前
DW发布了新的文献求助10
9秒前
DW发布了新的文献求助10
9秒前
万能图书馆的应助被Lily采纳,获得10
10秒前
DW发布了新的文献求助10
10秒前
DW发布了新的文献求助10
10秒前
10秒前
12345发布了新的文献求助10
11秒前
无花果的应助被wangfei采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157